GeneCentrix, founded in 2015, is a big-data bioinformatics company focused on developing innovative software tools for early-stage drug discovery. Their core mission is to enhance the efficiency and accuracy of drug development by leveraging advanced data analytics. The company offers a unique drug profiling platform that helps uncover unforeseen side effects, thereby reducing attrition rates in clinical trials. GeneCentrix primarily targets pharmaceutical companies and research institutions aiming to streamline their drug discovery processes.
Notable achievements include receiving the NIH Lab to Marketplace SBIR grant in 2015 and the NIH Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science SBIR grant in 2017. These accolades underscore the company's pioneering contributions to bioinformatics. GeneCentrix's impact lies in its ability to significantly reduce the time and cost associated with drug development, ultimately accelerating the availability of new therapies to patients.
